市場調查報告書
商品編碼
1399708
調強放射治療市場-放射類型(質子、電子、光子、碳離子)、應用(前列腺癌、肺癌、乳腺癌、腦癌和婦科癌症)、最終用途(醫院、獨立放射治療中心)-全球預測, 2023年- 2032Intensity Modulated Radiation Therapy Market-Radiation Type (Proton, Electron, Photon, Carbon-ion), Application (Prostate, Lung, Breast, Brain & Gynecological Cancer), End use (Hospital, Standalone Radiation Therapy Center)-Global Forecast, 2023-2032 |
預計從 2023 年到 2032 年,調強放射治療市場規模將擴大 5.2%。全球癌症發生率不斷上升,推動了對先進、精準治療方法的需求。調強放射治療提高了標靶腫瘤的準確性,同時最大限度地減少對周圍健康組織的損害,從而使其廣泛採用。例如,2023 年 10 月,UT Health San Antonio 推出了 Pluvicto,這是一種 FDA 批准的放射性藥物,專門針對前列腺特異性膜抗原陽性 (PSMA+) 轉移性去勢抵抗性前列腺癌提供放射治療。
政府支持性舉措的湧入、醫療保健基礎設施投資的增加以及創新放射治療解決方案的不斷開發正在滿足癌症患者和醫療保健提供者不斷變化的需求。此外,人們對調強放射治療 (IMRT) 益處的認知不斷提高,例如減少副作用和改善治療結果,將推動產業成長。
調強放射治療市場分為放射類型、應用、最終用途和區域。
預計從 2023 年到 2032 年,電子放射治療領域的行業佔有率將以 5.3% 的CAGR成長。這一成長歸因於電子放射治療表淺腫瘤的精確性和有效性。這種方式提供了改進的靶向性並最大限度地減少對周圍健康組織的損害。對先進和標靶癌症治療的需求不斷成長也將推動該領域的成長。
根據應用情況,婦科癌症領域的調強放射治療市場規模預計在 2023 年至 2032 年期間CAGR為 5.1%。這歸因於婦科癌症發病率的增加、對精確和有針對性的放射治療的高需求以及治療計劃的進步。 IMRT 能夠在不傷害健康組織的情況下提供聚焦輻射,這也將有助於其用於治療婦科癌症。
從區域來看,亞太調強放射治療市場預計從 2023 年到 2032 年將以 5.8% 的CAGR擴張。這是由於癌症患病率不斷上升、對先進治療方案的認知不斷提高以及醫療保健基礎設施的改善。尖端技術的採用、政府措施的增加以及對個人化癌症護理不斷成長的需求也將促進區域市場的擴張。
Intensity modulated radiation therapy market size is projected to expand at 5.2% from 2023 to 2032. The increasing incidence of cancer globally is fueling the demand for advanced and precise treatment methods. Intensity modulated radiation therapy offers enhanced accuracy in targeting tumors while minimizing damages to surrounding healthy tissues, leading to its widespread adoption. For instance, in October 2023, UT health San Antonio launched Pluvicto, an FDA-approved radiopharmaceutical to provide radiation treatment therapy specifically to prostate-specific membrane antigen positive (PSMA+) metastatic castration-resistant prostate cancer.
The influx of supportive government initiatives, rising investments in healthcare infrastructure, and the continuous development of innovative radiation therapy solutions are catering to the evolving needs of cancer patients and healthcare providers. Additionally, the rising awareness of the benefits of intensity modulated radiation therapy (IMRT), such as reduced side effects and improved treatment outcomes, will fuel the industry growth.
The intensity modulated radiation therapy market is segregated into radiation type, application, end-use, and region.
The industry share from the electron radiation therapy segment is projected to rise at 5.3% CAGR from 2023 to 2032. The growth is attributed to the precision and effectiveness of electron radiation in treating superficial tumors. This modality offers improved targeting and minimizes damages to the surrounding healthy tissues. The growing demand for advanced and targeted cancer treatments will also drive the segment growth.
Based on application, the intensity modulated radiation therapy market size from the gynecological cancer segment is projected to depict 5.1% CAGR during 2023-2032. This is ascribed to the increasing incidence of gynecological cancers, high demand for precise and targeted radiation therapy, and the advancements in treatment planning. The ability of IMRT to deliver focused radiation while sparing healthy tissues will also contribute to its adoption for treating gynecological cancers.
Regionally, the Asia Pacific intensity modulated radiation therapy market is projected to expand at 5.8% CAGR from 2023 to 2032. This is due to the increasing prevalence of cancer, rising awareness of advanced treatment options, and the improving healthcare infrastructure. The adoption of cutting-edge technologies, the increasing government initiatives, and the growing demand for personalized cancer care will also boost the regional market expansion.